Literature DB >> 26294105

Risk of optic pathway glioma in children with neurofibromatosis type 1 and optic nerve tortuosity or nerve sheath thickening.

Marc H Levin1, Gregory T Armstrong2, Julian H Broad3, Robert Zimmerman4, Larissa T Bilaniuk5, Tamara Feygin4, Yimei Li6, Grant T Liu7, Michael J Fisher8.   

Abstract

BACKGROUND/AIMS: Optic nerve tortuosity and nerve and sheath thickening are observed on MRI in some patients with neurofibromatosis type 1 (NF-1). This study aimed to determine if tortuosity and thickening are associated with the development of optic pathway glioma (OPG) and subsequent vision loss.
METHODS: Children with NF-1 who underwent brain MRI between 1992 and 2005, and had at least 1 year of subsequent visual acuity (VA) follow-up, were identified retrospectively. The baseline MRI was independently reviewed by three neuroradiologists for consensus assessment. Tortuosity was identified using validated operational criteria. Optic nerve and sheath thicknesses and VA at last follow-up were directly measured.
RESULTS: Of 132 evaluable children, seven (5%) had tortuosity on baseline MRI. 20 subjects (15%) ultimately developed OPG at a median of 1.9 years (range 7 months-8.0 years) following the baseline MRI. Subjects with tortuosity were significantly more likely to develop OPG than those without tortuosity (57% vs 13%, p=0.01). In subjects who developed OPG, the prevalence of tumour-related vision loss was not significantly different between those with and without baseline tortuosity (14% vs 4%, p=0.28). No difference existed between mean baseline optic nerve (2.3 vs 2.2 mm) or sheath (5.2 vs 5.4 mm) thicknesses comparing subjects who did and did not develop OPG.
CONCLUSIONS: Optic nerve tortuosity at baseline is associated with OPG development among patients with NF-1, but does not predispose to aggressive OPG with associated vision loss. Neither nerve nor sheath thickening at baseline is associated with OPG development. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  Imaging; Neoplasia; Optic Nerve; Vision; Visual pathway

Mesh:

Year:  2015        PMID: 26294105     DOI: 10.1136/bjophthalmol-2015-306958

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  6 in total

Review 1.  Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision.

Authors:  Peter M K de Blank; Michael J Fisher; Grant T Liu; David H Gutmann; Robert Listernick; Rosalie E Ferner; Robert A Avery
Journal:  J Neuroophthalmol       Date:  2017-09       Impact factor: 3.042

2.  Quantitative MRI criteria for optic pathway enlargement in neurofibromatosis type 1.

Authors:  Robert A Avery; Awais Mansoor; Rabia Idrees; Elijah Biggs; Mohammad Ali Alsharid; Roger J Packer; Marius George Linguraru
Journal:  Neurology       Date:  2016-05-11       Impact factor: 9.910

3.  Neurofibromatosis Type 1 Presenting with Ophthalmic Features: A Case Series.

Authors:  Gunjan Jain; Vaibhav Kumar Jain; Indra Kumar Sharma; Reena Sharma; Neeraj Saraswat
Journal:  J Clin Diagn Res       Date:  2016-11-01

4.  Predicting pediatric optic pathway glioma progression using advanced magnetic resonance image analysis and machine learning.

Authors:  Jared M Pisapia; Hamed Akbari; Martin Rozycki; Jayesh P Thawani; Phillip B Storm; Robert A Avery; Arastoo Vossough; Michael J Fisher; Gregory G Heuer; Christos Davatzikos
Journal:  Neurooncol Adv       Date:  2020-08-01

5.  Serial MRIs provide novel insight into natural history of optic pathway gliomas in patients with neurofibromatosis 1.

Authors:  Laura Sellmer; Said Farschtschi; Marco Marangoni; Manraj K S Heran; Patricia Birch; Ralph Wenzel; Victor-Felix Mautner; Jan M Friedman
Journal:  Orphanet J Rare Dis       Date:  2018-04-23       Impact factor: 4.123

6.  Risk of Optic Pathway Glioma in Neurofibromatosis Type 1: No Evidence of Genotype-Phenotype Correlations in A Large Independent Cohort.

Authors:  Giulia Melloni; Marica Eoli; Claudia Cesaretti; Donatella Bianchessi; Maria Cristina Ibba; Silvia Esposito; Giulietta Scuvera; Guido Morcaldi; Roberto Micheli; Elena Piozzi; Sabrina Avignone; Luisa Chiapparini; Chiara Pantaleoni; Federica Natacci; Gaetano Finocchiaro; Veronica Saletti
Journal:  Cancers (Basel)       Date:  2019-11-21       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.